Phase 3 CROSSING trial data show tezepelumab improved histologic remission and dysphagia versus placebo through week 52 in EoE.

Mark R. Corkins, MD, CNSC, FASPEN, AGAF, FAAP, reviews where pediatric probiotic evidence is strongest, why product quality varies, and which children should avoid them.

At AAP 2026, Carmen Tong, DO, discussed evaluating pediatric urinary symptoms and why behavioral strategies often come before medication.

New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.

Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.

A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.

Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.

A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.